Clinical Trials Browser

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

160 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03374839 2022-05-06

Nivo-TIL

Phase 1/2 Unknown

11 enrolled

Dermatologic

Melanoma

NCT03161756 2022-04-07

CHARLI

Phase 1/2 Unknown

72 enrolled

Dermatologic

Melanoma

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Phase 1 Unknown

219 enrolled

BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT04521075 2021-08-16

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Phase 1/2 Unknown

42 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Unknown

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Phase 1/2 Unknown

26 enrolled

Dermatologic

Uveal Melanoma

NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Phase 1 Unknown

30 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT04570683 2020-09-30

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Phase EARLY_PHASE1 Unknown

30 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT04021420 2020-08-20

SONIMEL01

Phase 1/2 Unknown

21 enrolled

Dermatologic

Melanoma

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

Unknown

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04250246 2020-01-31